Complement C3 and fatty liver disease in Rheumatoid arthritis patients: a cross-sectional study
- 2 September 2017
- journal article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 47 (10) , 728-735
Abstract
Recent evidence suggested a potential role of complement fraction C3 as a biomarker of nonalcoholic fatty liver disease (NAFLD) in the general population. Aim of this study was to evaluate the performance of C3 for prediction of NAFLD in RA patients. For the present study, consecutive RA patients were recruited. NAFLD was diagnosed according to predefined ultrasonographic (US) criteria. For comparison, the hepatic steatosis index (HSI) was calculated. Of 164 consecutive RA patients, 41 (25%) were diagnosed with NAFLD. The NAFLD group had a significant lower proportion of females (P = 0·04), higher BMI (P < 0·0001), C-reactive protein (P = 0·04), complement C3 (P = 0·001) and HSI (P = 0·003). In a logistic regression model, only male sex (OR 2·65, 95% CI: 1·08-6·50, P = 0·03), increasing BMI (OR 1·22, 95% CI: 1·02-1·46, P = 0·03) and complement C3 (OR 5·05, 95% CI: 1·06-23·93, P = 0·04) were associated with higher likelihood of being diagnosed with NAFLD. Finally, we built ROC curves for BMI, complement C3 and their combination for prediction of having NAFLD. The best cut-off for BMI was 28·5 kg/m2 and yielded a sensitivity of 66% and a specificity of 71%; the best cut-off for complement C3 was 1·23 g/L and yielded a sensitivity of 76% and a specificity of 64% for classification of NAFLD cases. Our results provide preliminary evidence for a potential role of complement C3 as a surrogate biomarker of NAFLD in RA patients.Keywords
This publication has 37 references indexed in Scilit:
- AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directionsDigestive and Liver Disease, 2017
- Cardiovascular risk management in rheumatoid arthritis: challenges aheadRheumatology, 2017
- Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre StudyPLOS ONE, 2017
- IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?Expert Review of Clinical Immunology, 2016
- Prevalence of Undiagnosed Diabetes in Rheumatoid ArthritisMedicine, 2016
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological AssociationHepatology, 2012
- Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective studyArthritis Research & Therapy, 2011
- The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort studyAnnals of the Rheumatic Diseases, 2011
- EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritisAnnals of the Rheumatic Diseases, 2010
- Proceedings: Liver function tests and liver biopsies in patients with rheumatoid arthritis.Annals of the Rheumatic Diseases, 1975